Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 3 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
5 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.

Sofosbuvir plus seraprevir therapy effective, safe in HCV genotype 1 infection

Stephen Padilla
02 Sep 2020

The combination therapy sofosbuvir-seraprevir appears to be effective and well tolerated in patients with chronic hepatitis C virus (HCV) genotype 1 infection without cirrhosis, results of a phase III trial have shown.

The study was conducted in China by Xiaoyu Wen and colleagues to assess the safety and efficacy of an all-oral interferon-free regimen of seraprevir, an NS3/4A protease inhibitor, and sofosbuvir in HCV patients for 12 weeks. The results were then presented at the recently concluded Digital International Liver Congress (ILC) 2020.

A total of 205 patients (aged 18–75 years) with noncirrhotic, chronic HCV genotype 2 infection were enrolled from 23 sites between 17 October 2018 and 17 January 2019. Of these, 178 (86.8 percent) were HCV treatment-naïve and 27 (13.2 percent) were treatment-experienced. Once-daily sofosbuvir 400 mg plus twice-daily seraprevir 100 mg was administered to patients for 12 weeks.

The primary efficacy endpoint of sustained virological response, defined as HCV RNA <15 IU/mL at 12 weeks after the end of treatment (SVR12), was assessed in all patients who received the study drug. The proportion of adverse events (AEs) resulting in premature discontinuation was the primary safety endpoint.

Of the participants, 203 completed the full treatment course and two discontinued therapy. Majority of the patients were female (54.6 percent), while 2.4 percent had genotype 1a and 97.6 percent had genotype 1b HCV infection. Mean age was 46.9 years (range, 24–73 years. Interferon treatment was administered to 13.2 percent of the participants. [ILC 2020, abstract THU391]

The full analysis set showed a 99.01-percent SVR12 rate, while the overall SVR4 rate was 99.51 percent. One patient relapsed after 4 weeks of follow-up, and another one relapsed after 12 weeks of follow-up.

Upper respiratory tract infection was the most frequent AE, occurring in 32 patients (15.6 percent). One discontinued treatment due to AEs. Eight others (3.9 percent) reported serious AEs, but none was deemed to be associated with the study drug.

“Treatment with the single-tablet sofosbuvir-seraprevir was highly effective and well tolerated in genotype 1 chronic HCV-infected population without cirrhosis,” the researchers said.

Previous studies assessing sofosbuvir in combination with other HCV therapy, particularly the HCV NS5A inhibitor velpatasvir and the HCV NS3/4A protease inhibitor voxilaprevir, have shown robust efficacy and high rates of SVR among patients across HCV genotypes in whom treatment with a direct-acting antiviral regimen had previously failed. [N Engl J Med 2017;376:2134-2146; Drugs 2018;78:577-587]

Furthermore, a meta-analysis of randomized controlled trials comparing sofosbuvir and nonsofosbuvir regimens in chronic HCV patients showed that sofosbuvir-treated individuals did not show an increased risk of cardiac outcomes, such as arrhythmia and bradycardia, indicating its relative safety. [Drug Saf 2018;41:77-86]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 3 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
5 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.